Genentech to Acquire Regor Pharmaceuticals' Next-Generation CDK Inhibitor Portfolio for $850 Million Upfront

On September 30, Regor Pharmaceuticals announced that it had reached an acquisition agreement with Genentech, a subsidiary of Roche, for the next-generation CDK inhibitors.

According to the agreement, Genentech willAcquisition of Regor Pharmaceuticals' Next-Generation CDK Inhibitor for $850 Million in Cash UpfrontRegor Pharmaceuticals is also eligible for additional cash payments, contingent upon achieving future development, regulatory, and commercial milestones!

Genentech will be responsible for global clinical development, manufacturing, and commercialization. Regor Pharmaceuticals will continue to manage the two ongoing Phase 1 trials until completion.

The proposed transaction is expected to be completed in the fourth quarter of 2024.The completion of the proposed transaction is subject to the satisfaction of customary closing conditions.

Regor has a series of potentially differentiated candidate drugs, including those related to metabolism, oncology, and autoimmune diseases; its pipeline includes two CDK inhibitors under research, namelyRGT-419B and QR-6401RGT-419B is a CDK2/4/6 inhibitor currently undergoing two Phase I clinical trials for HR+/HER2- breast cancer. QR-6401 is a CDK2 inhibitor currently in the preclinical stage.

Dr. Xiaoyang Qiu, founder and CEO of Regor Pharmaceuticals, said, "Genentech is fully capable of maximizing the potential of these novel therapies to benefit breast cancer patients worldwide. We are proud of the robust data we have achieved so far. We look forward to bringing more innovative therapies to patients around the world."

About Regor Pharmaceuticals (USA)

Regor Pharmaceuticals (USA) is a subsidiary of Regor Therapeutics Group, a clinical-stage biotechnology company dedicated to developing innovative and clinically differentiated drugs to address significant unmet needs in oncology, metabolism, and autoimmune diseases. By leveraging its proprietary CARD (Computer Accelerated Rational Discovery) platform, Regor Therapeutics Group has advanced more than a dozen internally discovered assets into various stages of preclinical and clinical development, validating its highly efficient ecosystem to accelerate the discovery of innovative therapeutic agents.